AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options, ...

AngioDynamics has obtained an FDA green light for its NanoKnife prostate cancer ablation system, designed to precisely target and destroy tissue without delivering excess heat and the unintended ...

Attendees will gain insights into the NanoKnife System’s proprietary irreversible electroporation (IRE) technology and how it is poised to become the standard, function-preserving treatment for men ...

AngioDynamics has won US Food and Drug Administration (FDA) clearance for its NanoKnife system to be used in prostate cancer patients. The system, which was already FDA-cleared for the surgical ...

The clearance for the NanoKnife System for prostate tissue ... ablating prostate tissue in patients with intermediate-risk prostate cancer (PCa). The latest regulatory clearance is a significant ...

It is worthwhile to note that the PRESERVE clinical study assessed the safety and effectiveness of the NanoKnife System for ablating prostate tissue in patients with intermediate-risk prostate cancer ...

"The NanoKnife System minimizes the life-altering ... of the NanoKnife System in patients with immediate-risk prostate cancer. The results reinforced findings from more than 32 other studies ...

Shares of AngioDynamics hit a 52-week high after the company's NanoKnife System for prostate ... System in patients with immediate-risk prostate cancer. The results reinforced findings from ...